Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

a0FVy00000AsB3xMAF - 707 COSA 2026-Symbiotic-Lung-01 (Ph 3 NSCLC) TiP poster - EFC

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

Symbiotic-Lung-01: a phase 3 trial of a PD-1/VEGF bispecific antibody, tivunatamig (PF-08634404,) vs pembrolizumab in combination with platinum-based chemotherapy in first-line for locally advanced or metastatic non-small cell lung cancer

Scientific presentation
Scientific presentation mobile

Web preview is not available

Try directly downloading the file.